BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25641047)

  • 1. The targeting of human and mouse B lymphocytes by dasatinib.
    Oksvold MP; Duyvestyn JM; Dagger SA; Taylor SJ; Forfang L; Myklebust JH; Smeland EB; Langdon WY
    Exp Hematol; 2015 May; 43(5):352-363.e4. PubMed ID: 25641047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
    Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
    PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM; Cosimo E; Leach MT; Michie AM
    Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
    Moyo TK; Wilson CS; Moore DJ; Eischen CM
    Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.
    Yang C; Lu P; Lee FY; Chadburn A; Barrientos JC; Leonard JP; Ye F; Zhang D; Knowles DM; Wang YL
    Leukemia; 2008 Sep; 22(9):1755-66. PubMed ID: 18596745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
    Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
    Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
    Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
    J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Blake S; Hughes TP; Mayrhofer G; Lyons AB
    Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
    Schade AE; Schieven GL; Townsend R; Jankowska AM; Susulic V; Zhang R; Szpurka H; Maciejewski JP
    Blood; 2008 Feb; 111(3):1366-77. PubMed ID: 17962511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New roles for B cell receptor associated kinases: when the B cell is not the target.
    Nguyen PH; Niesen E; Hallek M
    Leukemia; 2019 Mar; 33(3):576-587. PubMed ID: 30700840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
    Nerreter T; Distler E; Köchel C; Einsele H; Herr W; Seggewiss-Bernhardt R
    Exp Hematol; 2013 Jul; 41(7):604-614.e4. PubMed ID: 23466625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
    Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
    J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
    Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R
    Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
    Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
    Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum.
    Bendall SC; Simonds EF; Qiu P; Amir el-AD; Krutzik PO; Finck R; Bruggner RV; Melamed R; Trejo A; Ornatsky OI; Balderas RS; Plevritis SK; Sachs K; Pe'er D; Tanner SD; Nolan GP
    Science; 2011 May; 332(6030):687-96. PubMed ID: 21551058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
    Wölfl M; Schwinn S; Yoo YE; Reß ML; Braun M; Chopra M; Schreiber SC; Ayala VI; Ohlen C; Eyrich M; Beilhack A; Schlegel PG
    Blood; 2013 Aug; 122(7):1203-13. PubMed ID: 23836556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.